
News|Poll|March 27, 2015
Have You Heard This (Week's) News?
Author(s)Susan Kweskin
Advertisement
Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema. The FDA previously approved ranibizumab (Lucentis, Roche) for the same indication.
Eylea (aflibercept) injection is also indicated for treatment of which of the following?
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
2
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
3
Age, Not Menopause Stage, Drives Cortical Volume Reduction in Midlife Women, New Study Suggests
4
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms
5